HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03625350
Contributor : Nicolas André Connect in order to contact the contributor
Submitted on : Wednesday, March 30, 2022 - 6:29:25 PM
Last modification on : Friday, April 1, 2022 - 3:43:31 AM

Identifiers

Collections

Citation

Claudia Pasqualini, Jonathan Rubino, Caroline Brard, Lydie Cassard, Nicolas André, et al.. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer, Elsevier, 2021, 150, pp.53-62. ⟨10.1016/j.ejca.2021.03.032⟩. ⟨hal-03625350⟩

Share

Metrics

Record views

2